Meta-analysis Of Efficacy And Safety Of Neoadjuvant Immunotherapy And Neoadjuvant Chemotherapy In The Treatment Of Non-small Cell

Objective To compare the efficacy and safety of neoadjuvant immunotherapy and neoadjuvant chemotherapy in the treatment of stage I-III non-small cell lung cancer(NSCLC),and to provide a reference for the neoadjuvant treatment of NSCLC.Methods The published studies comparing the efficacy and safety of neoadjuvant immunotherapy and neoadjuvant chemotherapy were collected.The included studies were analyzed by Review Manager version 5.4 software.Results Thirteen studies met the inclusion criteria.The total sample size was 1366 cases,including 597 cases in the neoadjuvant immunotherapy combined with chemotherapy group and 769 cases in the neoadjuvant chemotherapy group.Result The rate of major pathological response,complete pathological response,surgical resection rate,incidence of treatment-related adverse events and incidence of serious adverse events in patients receiving neoadjuvant immunotherapy were 21.3%,9.1%,91.5%,43.8% and 6.5%,respectively.The major pathological response rate,complete pathological response rate,surgical resection rate,incidence of treatment-related adverse events and incidence of serious adverse events were 20.6%,5.7%,85.8%,43.8% and 13.8%,respectively,after receiving neoadjuvant chemotherapy.Among them,there were statistically significant differences in surgical resection rate and incidence of treatment-related adverse events(P < 0.05).In addition,we found that neoadjuvant chemotherapy had a better lesion remission rate(32.4%)and neoadjuvant immunotherapy had a better disease stabilization rate(69.8%).Conclusions Neoadjuvant immunotherapy is a safe,effective and feasible treatment for non-small cell lung cancer,with better lesion stabilization rate,higher surgical resection rate and less incidence of treaty-related adverse events,so it has a relatively practical application prospect.